Manipulating the consequential effect: An alternative approach to reducing pelvic radiation disease other than dose reduction

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 1, 2011, Pages 25-28

  Wedlake, Linda J ^a   Andreyev, H Jervoise N ^b  

^a Department of Nutrition and Dietetics ^*  (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL DISEASE; HUMAN; PELVIS TUMOR; RADIATION INJURY; REVIEW;

GASTROINTESTINAL DISEASES; HUMANS; PELVIC NEOPLASMS; RADIATION INJURIES;

EID: 79954526440     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328343ad2f     Document Type: Review

References (50)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917.
2. National Cancer Survivorship Initiative Vision. http://wwwnsciorguk. 2010.
3. Bergmark K, Avall-Lundqvist E, Dickman P, et al. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand 2002; 81:443-450. (Pubitemid 34527151)
4. Hauer-Jensen M, Wang J, Denham JW. Bowel injury: current and evolving management strategies. Semin Radiat Oncol 2003; 13:357-371. (Pubitemid 36962656)
5. Andreyev HJN. Gastrointestinal problems following pelvic radiotherapy: the past, the present and the future. Clin Oncol 2007; 19:790-799. (Pubitemid 350011927)
6. Vicary P, Johnson M. Maher J, and Patient representatives of the MacMillan late effects group. To my oncologist: an open letter from a patient at the end of follow-up. Clin Oncol (R Coll Radiol) 2007; 19:746-747. (Pubitemid 350011926)
7. Andreyev HJN, Wotherspoon A, Denham JD, Hauer-Jensen M. Defining pelvic-radiation disease for the survivorship era. Lancet Oncol 2010; 11:310-312.
8. Mameghan H, Fisher R, Mameghan J, et al. Bowel complications after radiotherapy for carcinoma of the prostate: the volume effect. Int J Radiat Oncol Biol Phys 1990; 18:315-320. (Pubitemid 20097525)
9. Schultheiss T, Lee R, Hunt M, et al. Late GI & GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:3-11. (Pubitemid 27090129)
10. Wang C, Leung S, Chen H, et al. The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys 1998; 40:85-90.
11. Weiss E, Hirnle P, Arnold-Bofinger H, et al. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999; 53:37-44.
12. Denham JW, O'Brien PC, Dunstan RH, et al. Is there more than one late radiation proctitis syndrome. Radiother Oncol 1999; 51:43-53. (Pubitemid 29244090)
13. O'Brien PC, Franklin CI, Poulsen MG, et al. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term followup of a phase III trial: Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54:442-449. (Pubitemid 35286810)
14. Vargas C, Martinez A, Kestin LL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive imageguided radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:1297-1308. (Pubitemid 40982047)
15. Heemsbergen WD, Peeters ST, Koper PC, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006; 66:3-10. (Pubitemid 44175664)
16. Zelefsky M, Levin EJ, Hunt MA, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70:1124-1129. (Pubitemid 351296130)
17. Wedlake LJ, Thomas K, Lalji A, et al. Predicting late effects of pelvic radiotherapy: is there a better approach? Int J Radiat Oncol Biol Phys 2010; 78:1163-1170.
18. Gulliford SL, Partridge M, Sydes MR, et al. A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity. Radiother Oncol 2010; 94:241-247.
19. Larsen A, Hovdenak N, Karlsdottir A, et al. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol Suppl 2004; 39:1113-1118. (Pubitemid 39536401)
20. Christensen E, Pintilie M, Evans KR, et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009; 15:5576-5583.
21. Wedlake L, McGough C, Hackett C, et al. Can biological markers act as noninvasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa? Aliment Pharmacol Ther 2008; 27:980-987. (Pubitemid 351537649)
22. Hille A, Rave-Fränk M, Christiansen H, et al. Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: results of a prospective study. Scand J Gastroenterol 2009; 44:936-946.
23. Lutgens LC, Deutz NE, Gueulette J, et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 2003; 57:1067-1074. (Pubitemid 37324125)
24. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic predisposition pending between fiction and reality. J Cell Mol Med 2007; 11:1031-1051. (Pubitemid 350037048)
25. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47:455-460. (Pubitemid 351280713)
26. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 2008; 27:589-596. (Pubitemid 351715387)
27. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76 (3 Suppl):S3-9.
28. Sullivan M. Dependence of radiation diarrhoea on the presence of bile in the intestine. Nature 1962; 195:1217-1218.
29. Sokol A, Lipson L, Morgenstern L, Hiatt N. Protection against lethal irradiation injury by pancreatic enzyme exclusion. Surg Forum 1967; 18:387-389.
30. Morgenstern L, Patin CS, Krohn HL, Hiatt N. Prolongation of survival in lethally irradiated dogs by pancreatic duct ligation. Arch Surg 1970; 101:586-589.
31. Hauer-Jensen M, Sauer T, Berstad T, Nygaard K. Influence of pancreatic secretion on late radiation enteropathy in the rat. Acta Radiol Oncol 1985; 24:555-560. (Pubitemid 16183313)
32. Wang JI, Zheng H, Sung CC, Hauer-Jensen M. The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 1999; 45:1289-1296.
33. Wang J, Zheng H, Hauer-Jensen M. Influence of Short-Term Octreotide Administration on Chronic Tissue Injury, Transforming Growth Factor beta (TGF-beta) Overexpression, and Collagen Accumulation in Irradiated Rat Intestine. J Pharmacol Exp Ther 2001; 297:35-42. (Pubitemid 32242560)
34. Onal C, Kayaselcuk F, Topkan E, et al. Protective effects of melatonin and octreotide against radiation-induced intestinal injury. Dig Dis Sci 2010. [Epub ahead of print]
35. O'Keefe SJ. Nutrition and gastrointestinal disease. Scand J Gastroenterol Suppl. 1996; (Suppl 220):52-59. (Pubitemid 26338383)
36. O'Keefe SJ, Lee RB, Anderson FP, et al. Physiological effects of enteral and parenteral feeding on pancreaticobiliary secretion in humans. Am J Physiol Gastrointest Liver Physiol 2003; 284:G27-G36. (Pubitemid 36076247)
37. McGough C, Baldwin C, Frost G, Andreyev HJN. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer 2004; 90:2278-2287. (Pubitemid 38961889)
38. Salminen E, Elomaa I, Minkkinen J, et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988; 39:435-437.
39. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001; 13:391-396. (Pubitemid 32319905)
40. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007; 13:912-915. (Pubitemid 46470303)
41. Delia P, Sansotta G, Donato V, et al. Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience. Dig Liver Dis 2002; 34 (Suppl 2):S84-S86.
42. Giralt J, Regadera JP, Verges R, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008; 71:1213-1219.
43. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 2010; 5.
44. Gaugler MH, Vereycken-Holler V, Squiban C, et al. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 2005; 163:479-487. (Pubitemid 41490643)
45. Haydont V, Gilliot O, Rivera S, et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol Biol Phys 2007; 68:1471-1482. (Pubitemid 47176803)
46. Haydont V, Bourgier C, Pocard M, et al. Pravastatin Inhibits the Rho/CCN2/ extracellular matrix cascade in human fibrosis explants and improves radiationinduced intestinal fibrosis in rats. Clin Cancer Res 2007; 13 (18 Pt 1):5331-5340. (Pubitemid 47510357)
47. Ostrau C, Hü lsenbeck J, Herzog M, et al. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother Oncol 2009; 92:492-499.
48. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76:523-532. (Pubitemid 30232452)
49. Ward WF, Lin PJ, Wong PS, et al. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 1993; 135:81-87. (Pubitemid 23230669)
50. Wang LW, Fu XL, Clough R, et al. Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat Res 2000; 153:405-410. (Pubitemid 30185393)